Nasus Pharma (NSRX) Total Non-Current Liabilities (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Total Non-Current Liabilities came in at $2.4 million in Q2 2025, up 12.36% on a QoQ basis from $2.1 million in Q4 2024.
Nasus Pharma (NSRX) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Total Non-Current Liabilities data on file, last reported at $2.4 million in Q2 2025.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $2.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.4 million (changed N/A YoY) and the FY2024 annual result came in at $2.1 million, changed N/A from the prior year.
- Total Non-Current Liabilities improved to $2.4 million in Q2 2025, from $2.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.4 million in Q2 2025 to a low of $2.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.87 Bn | 633.12 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 470.41 Bn | 463.84 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 303.87 Bn | 296.18 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.75 Bn | 252.85 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 236.40 Bn | 222.41 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 182.11 Bn | 178.93 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.54 Bn | 147.84 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.30 Bn | 102.13 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Nasus Pharma | 31.88 Mn | 31.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.39 Mn |
| Dec 31, 2024 | 2.13 Mn |